Biosimilars are a
The Biosimilars Council advocates to increase patient access to lifesaving, affordable biosimilar medicines. Our members include manufacturers and stakeholders working to develop biosimilar medicines for the U.S. market.
Join Us October 21–23 for GRx+Biosims 2024
GRx+Biosims™ 2024 is the leading scientific, regulatory and policy event for the U.S. generics and biosimilars industry! Register now to advance your professional development and gain great understanding of policy that impacts our industry—all while learning directly from FDA experts.
U.S. Generic & Biosimilar Medicines Savings Report
Representing 90% of prescriptions filled but only 13% of spending, generics and biosimilars are essential to America’s patients and the U.S. healthcare system. The 2024 U.S. Generic & Biosimilar Medicines Savings Report shows savings will continue to grow—with $445 billion saved in 2023, alone.
Press Releases
What’s New
Approved Biosimilars in the U.S.
$180B
Potential Savings for Patients and Payers
694M
Days of Patient Therapy with Biosimilars
Incremental Days of Biosimilar Therapy
